Formulation and Stability Study of Omeprazole Oral Liquid Suspension for Pediatric Patients

被引:11
|
作者
Boscolo, Oriana [1 ]
Perra, Francesco [1 ,2 ]
Salvo, Leandro [1 ]
Buontempo, Fabian [1 ,3 ]
Lucangioli, Silvia [1 ,4 ]
机构
[1] Univ Buenos Aires, Buenos Aires, DF, Argentina
[2] Univ Cagliari, Cagliari, Italy
[3] Hosp Pediat JP Garrahan, Buenos Aires, DF, Argentina
[4] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina
关键词
omeprazole; formulation; stability study; pediatric; acid-related diseases; PROTON PUMP INHIBITORS;
D O I
10.1177/0018578719844704
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives:To develop and to study the physicochemical and microbiological stability of omeprazole liquid oral formulations used as therapeutic agent in many acid-related disorders, for pediatric use. Furthermore, to optimize and validate a stability-indicating high-performance liquid chromatography (HPLC) method for the analysis of omeprazole in the studied formulations.Method:Oral liquid suspensions of omeprazole were prepared at 2 mg/mL using crushed omeprazole pellets (formulation A) and pure omeprazole (formulation B) with a complete vehicle including humectant, suspending, sweetening, antioxidant, and flavoring agents. Samples were stored at 4 degrees C and 25 degrees C. Omeprazole content of each formulation was analyzed in triplicate using micro-HPLC at 0, 3, 7, 14, 30, 60, 90, 120, and 150 days. Other parameters were also determined, such as appearance, pH, resuspendibility, and viscosity. Microbiological studies were conducted according to the United Stated Pharmacopeia (USP) guidelines for non-sterile products.Results:Formulation A stayed physicochemical and microbiologically stable at refrigerated (4 degrees C) conditions during at least 150 days and it only stayed stable during 14 days at 25 degrees C. Formulation B was stayed physicochemical and microbiologically stable at refrigerated (4 degrees C) conditions at least 90 days, but it is not recommended to store at 25 degrees C for more than 1 day.Conclusions:Formulation A and formulation B can be stored for at least 150 and 90 days, respectively, at refrigerated conditions. Formulation A can be stored at room temperature for 14 days. Both formulations are perfectly suitable for pediatric patients who are usually notable to swallow solid oral formulations. The proposed analytical method was suitable for the study of stability of different formulations.
引用
收藏
页码:314 / 322
页数:9
相关论文
共 50 条
  • [11] Formulation, Quality Control and Stability Study of Pediatric Oral Dextrose Gel
    Lamy, Edouard
    Orneto, Caroline
    Ali, Oumil Her Abdou
    Kireche, Lyna
    Mathias, Fanny
    Bouguergour, Cyrielle
    Peyron, Florence
    Primas, Nicolas
    Sauzet, Christophe
    Piccerelle, Philippe
    Maillotte, Anne-Marie
    Brevaut-Malaty, Veronique
    Rathelot, Pascal
    Vanelle, Patrice
    Curti, Christophe
    PHARMACEUTICALS, 2025, 18 (02)
  • [12] Design and stability of pediatric oral formulation of imatinib
    Hinterlang, Melanie
    Gendron, Amandine
    Fleury, Thomas
    Rieutord, Andre
    Vrana, Anastasia
    Schlatter, Joel
    Annereau, Maxime
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (02) : 337 - 342
  • [13] Investigation of omeprazole stability in oral suspensions for pediatric use prepared extemporaneously from omeprazole capsules
    Milic, Jela
    Radojkovic, Branko
    Stojanovic, Biljana
    Draskovic, Jasmina
    Mirasevic, Slavica
    Djordjevic, Sanela
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 511 (02) : 1147 - 1148
  • [14] Stability of an extemporaneous oral liquid aprepitant formulation
    Dupuis, L. Lee
    Lingertat-Walsh, Karen
    Walker, Scott E.
    SUPPORTIVE CARE IN CANCER, 2009, 17 (06) : 701 - 706
  • [15] Stability of an extemporaneous oral liquid aprepitant formulation
    L. Lee Dupuis
    Karen Lingertat-Walsh
    Scott E. Walker
    Supportive Care in Cancer, 2009, 17 : 701 - 706
  • [16] Evaluation of stability and viscosity of omeprazole immediate-release oral suspension at a concentration suitable for pediatric use (2 mg/ml)
    Burnett, J
    Balkin, ER
    GASTROENTEROLOGY, 2005, 128 (04) : A524 - A524
  • [17] DEVELOPING A PEDIATRIC ORAL SUSPENSION FORMULATION OF ABROCITINIB: A RELATIVE BIOAVAILABILITY AND PALATABILITY ASSESSMENT STUDY IN ADULTS
    Shahin, M.
    Tripathy, S.
    Winton, J.
    Wan, X.
    Stanciu, D.
    Le, V.
    Kavetska, O.
    Malhotra, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S84 - S84
  • [18] Delayed-release oral suspension of omeprazole for the treatment of erosive esophagitis and gastroesophageal reflux disease in pediatric patients: a review
    Monzani, Alice
    Oderda, Giuseppina
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2010, 3 : 17 - 25
  • [19] Pharmacodynamics of omeprazole suspension in critically ill pediatric liver/intestinal transplant patients
    Bergman, KL
    Kaufman, S
    Collier, D
    Rebuck, JA
    Brown, C
    Olsen, KM
    CRITICAL CARE MEDICINE, 1999, 27 (01) : A171 - A171
  • [20] Captopril oral solution for pediatric use: formulation, stability study and palatability assessment in vivo
    Dysarz, Leticia Pereira
    Tavares, Melanie
    Vicosa, Alessandra Lifsitch
    Ribeiro, Mara Fernandes
    de Silva Teixeira, Rafaela Gomes
    Elias, Sabrina Calil
    Mattos da Silva, Marcio Robert
    dos Santos, Elisabete Pereira
    Ricci-Junior, Eduardo
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 58